{"id":2945,"date":"2026-09-03T12:59:00","date_gmt":"2026-09-03T16:59:00","guid":{"rendered":"https:\/\/www.lifetein.com\/blog\/?p=2945"},"modified":"2026-09-03T12:59:02","modified_gmt":"2026-09-03T16:59:02","slug":"ova-should-my-peptide-be-conjugated-to-it","status":"publish","type":"post","link":"https:\/\/www.lifetein.com\/blog\/ova-should-my-peptide-be-conjugated-to-it\/","title":{"rendered":"OVA: Should My Peptide Be Conjugated To It?"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"500\" height=\"500\" src=\"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/09\/OVA1.webp\" alt=\"OVA\" class=\"wp-image-2978\" srcset=\"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/09\/OVA1.webp 500w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/09\/OVA1-300x300.webp 300w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/09\/OVA1-150x150.webp 150w\" sizes=\"(max-width: 500px) 100vw, 500px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Peptide-carrier protein conjugation<\/strong>\u00a0is a cornerstone technique in immunology, enabling the production of high-affinity antibodies against small peptide antigens. Because peptides alone (typically &lt;5,000 Da) are too small to elicit a robust immune response, they must be chemically linked to larger\u00a0<strong>carrier proteins<\/strong>\u00a0that provide T-helper epitopes and stimulate B-cell activation<a href=\"https:\/\/www.lifetein.com\/chat\/261089-Why-is-conjugation-of-the-peptide-to-a-carrier-protein-necessary?srsltid=AfmBOooVAiysV01EB22cIu6C8-YXYUN3Byd8UlM4q-J6zs3YFEJ_NlZh\" target=\"_blank\" rel=\"noopener\"><\/a>. Among the available carriers, including\u00a0<strong>KLH, BSA, and CRM197<\/strong>, <strong>Ovalbumin (OVA)<\/strong>\u00a0occupies a distinct niche. However, the decision to conjugate your peptide to OVA is not interchangeable with other carriers; it requires a clear understanding of OVA&#8217;s unique properties, its optimal role in antibody workflows, and its limitations. This article provides a framework for determining whether OVA conjugation is the right choice for your research.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 id=\"key-takeaways\" class=\"wp-block-heading\">Key Takeaways<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>OVA (Ovalbumin)<\/strong>&nbsp;is a ~45 kDa glycoprotein isolated from chicken egg whites, widely used as a&nbsp;<strong>secondary carrier protein<\/strong>&nbsp;for screening and confirmation assays.<\/li>\n\n\n\n<li><strong>Do not use OVA for primary immunizations<\/strong>&nbsp;if your goal is to generate high-titer antibodies;&nbsp;<strong>KLH<\/strong>&nbsp;is the gold standard for this purpose due to its superior immunogenicity.<\/li>\n\n\n\n<li>OVA&#8217;s primary value lies in its role as an&nbsp;<strong>independent carrier for ELISA coating<\/strong>&nbsp;and specificity screening, allowing you to confirm that antibodies target the peptide epitope rather than the carrier protein.<\/li>\n\n\n\n<li>OVA offers advantages in specific research contexts, such as&nbsp;<strong>invertebrate studies<\/strong>&nbsp;where mammalian proteins like BSA may cause cross-reactivity.<\/li>\n\n\n\n<li>OVA contains&nbsp;<strong>20 lysine residues<\/strong>&nbsp;(21 primary amines including the N-terminus), providing multiple conjugation sites for peptide coupling.<\/li>\n\n\n\n<li>Custom OVA conjugation services are available through specialized providers like&nbsp;<strong>LifeTein<\/strong>, enabling researchers to obtain high-quality conjugates for their specific applications.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"why-conjugate-a-peptide-to-ova\" class=\"wp-block-heading\">Why Conjugate a Peptide to OVA?<\/h2>\n\n\n\n<h4 id=\"the-immunogenicity-barrier\" class=\"wp-block-heading\">The Immunogenicity Barrier<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Synthetic peptides are inherently&nbsp;<strong>poor immunogens<\/strong>&nbsp;due to their small size. Without a carrier, they fail to cross-link B-cell receptors or activate T-helper cells effectively<a href=\"https:\/\/www.lifetein.com\/chat\/261089-Why-is-conjugation-of-the-peptide-to-a-carrier-protein-necessary?srsltid=AfmBOooVAiysV01EB22cIu6C8-YXYUN3Byd8UlM4q-J6zs3YFEJ_NlZh\" target=\"_blank\" rel=\"noopener\"><\/a>. Conjugation to a carrier protein like OVA overcomes this limitation by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Increasing molecular size<\/strong>, allowing the conjugate to be processed and presented by antigen-presenting cells<a href=\"https:\/\/www.lifetein.com\/chat\/261089-Why-is-conjugation-of-the-peptide-to-a-carrier-protein-necessary?srsltid=AfmBOooVAiysV01EB22cIu6C8-YXYUN3Byd8UlM4q-J6zs3YFEJ_NlZh\" target=\"_blank\" rel=\"noopener\"><\/a>.<\/li>\n\n\n\n<li><strong>Providing T-helper epitopes<\/strong>, which facilitate isotype switching and memory responses<a href=\"https:\/\/www.lifetein.com\/chat\/261089-Why-is-conjugation-of-the-peptide-to-a-carrier-protein-necessary?srsltid=AfmBOooVAiysV01EB22cIu6C8-YXYUN3Byd8UlM4q-J6zs3YFEJ_NlZh\" target=\"_blank\" rel=\"noopener\"><\/a>.<\/li>\n\n\n\n<li><strong>Preventing immune tolerance<\/strong>, which can occur upon repeated exposure to a peptide alone<a href=\"https:\/\/www.lifetein.com\/chat\/261089-Why-is-conjugation-of-the-peptide-to-a-carrier-protein-necessary?srsltid=AfmBOooVAiysV01EB22cIu6C8-YXYUN3Byd8UlM4q-J6zs3YFEJ_NlZh\" target=\"_blank\" rel=\"noopener\"><\/a>.<\/li>\n<\/ul>\n\n\n\n<h4 id=\"ovas-distinctive-properties\" class=\"wp-block-heading\">OVA&#8217;s Distinctive Properties<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">OVA is the&nbsp;<strong>major protein of chicken egg whites<\/strong>, with a molecular weight of approximately&nbsp;<strong>45 kDa<\/strong><a href=\"https:\/\/www.lifetein.com\/Peptide_Modifications_Carrier_Proteins.html?srsltid=AfmBOoqY3q8sJGx3gHeZ2g1ZoSyMNb2I1IqQBo4OBMSDMeLMPOpU8qSM\" target=\"_blank\" rel=\"noopener\"><\/a>. It is a well-characterized, single-domain glycoprotein with a known immunogenicity profile. Unlike BSA (67 kDa) or KLH (up to 13,000 kDa), OVA offers a&nbsp;<strong>mid-size carrier option<\/strong>&nbsp;that balances solubility, stability, and immunogenicity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.lifetein.com\/Peptide_Modifications_Carrier_Proteins.html?srsltid=AfmBOooKaOBognB4ltuO4oDZyTkOVEiQ6SdVy2ycY_4VVsNFajYgS2yM\" target=\"_blank\" rel=\"noopener\">Find more peptide conjugation here.<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"when-should-you-choose-ova-conjugation\" class=\"wp-block-heading\">When Should You Choose OVA Conjugation?<\/h2>\n\n\n\n<h4 id=\"for-specificity-screening-and-elisa-coating\" class=\"wp-block-heading\">For Specificity Screening and ELISA Coating<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The&nbsp;<strong>primary and most compelling use<\/strong>&nbsp;of OVA conjugates is as a&nbsp;<strong>secondary carrier for screening and confirmation assays<\/strong>. The standard workflow in antibody production involves:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><strong>Immunizing<\/strong>&nbsp;with a&nbsp;<strong>KLH-peptide conjugate<\/strong>&nbsp;(KLH is more immunogenic).<\/li>\n\n\n\n<li><strong>Screening<\/strong>&nbsp;the resulting antiserum using an&nbsp;<strong>OVA-peptide conjugate<\/strong>&nbsp;in ELISA.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">This approach is critical because the immune system reacts to the\u00a0<strong>entire peptide-protein conjugate<\/strong>, meaning antibodies will be raised against the peptide, the linker, and the carrier protein<a href=\"https:\/\/www.lifetein.com\/Peptide_Modifications_Carrier_Proteins.html?srsltid=AfmBOoqY3q8sJGx3gHeZ2g1ZoSyMNb2I1IqQBo4OBMSDMeLMPOpU8qSM\" target=\"_blank\" rel=\"noopener\"><\/a>. By using a\u00a0<strong>different carrier for screening<\/strong>\u00a0(OVA) than for immunization (KLH), you can\u00a0<strong>confirm that antibodies are specific to the peptide epitope<\/strong>\u00a0rather than the carrier backbone<a href=\"https:\/\/www.lifetein.com\/Peptide_Modifications_Carrier_Proteins.html?srsltid=AfmBOoqY3q8sJGx3gHeZ2g1ZoSyMNb2I1IqQBo4OBMSDMeLMPOpU8qSM\" target=\"_blank\" rel=\"noopener\"><\/a>. As LifeTein notes, OVA is &#8220;often used as a second carrier protein to confirm that antibodies are specific for the peptide rather than the carrier protein (e.g. BSA)&#8221;.<\/p>\n\n\n\n<h4 id=\"for-studies-involving-invertebrate-species\" class=\"wp-block-heading\">For Studies Involving Invertebrate Species<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">If your research involves&nbsp;<strong>invertebrate models<\/strong>, OVA is an excellent choice. Because OVA is derived from chicken, it is&nbsp;<strong>phylogenetically distant<\/strong>&nbsp;from mammalian proteins, reducing the risk of cross-reactivity that could arise when using mammalian carriers like BSA.<\/p>\n\n\n\n<h4 id=\"for-competitive-assay-formats\" class=\"wp-block-heading\">For Competitive Assay Formats<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Matched&nbsp;<strong>BSA and OVA conjugates<\/strong>&nbsp;support advanced assay formats, including&nbsp;<strong>competitive ELISA<\/strong>, where the use of two different carriers helps distinguish true peptide-specific binding from carrier-directed signals.<\/p>\n\n\n\n<h4 id=\"for-longterm-peptide-storage\" class=\"wp-block-heading\">For Long-Term Peptide Storage<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Similar to BSA, OVA can serve as a&nbsp;<strong>stabilizing agent<\/strong>&nbsp;for peptide storage, improving solubility and preventing aggregation<a href=\"https:\/\/www.lifetein.com\/chat\/261089-Why-is-conjugation-of-the-peptide-to-a-carrier-protein-necessary?srsltid=AfmBOooVAiysV01EB22cIu6C8-YXYUN3Byd8UlM4q-J6zs3YFEJ_NlZh\" target=\"_blank\" rel=\"noopener\"><\/a>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"when-should-you-avoid-ova-conjugation\" class=\"wp-block-heading\">When Should You Avoid OVA Conjugation?<\/h2>\n\n\n\n<h4 id=\"for-primary-immunizations\" class=\"wp-block-heading\">For Primary Immunizations<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">OVA is&nbsp;<strong>not the optimal choice for primary immunizations<\/strong>. Its immunogenicity is&nbsp;<strong>significantly lower<\/strong>&nbsp;than KLH, which remains the gold standard carrier for generating high-titer antibodies. As one source notes, &#8220;KLH is the gold standard for primary immunization due to its massive size and immunogenicity, while BSA and OVA are reserved for downstream ELISA screening&#8221;. If your goal is to maximize antibody titers,&nbsp;<strong>KLH is the preferred carrier<\/strong>.<\/p>\n\n\n\n<h4 id=\"when-ova-itself-is-the-target-of-study\" class=\"wp-block-heading\">When OVA Itself Is the Target of Study<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">If your research involves chicken ovalbumin as a protein of interest (e.g., studying the OVA-specific immune response in mouse models), using OVA as a carrier would introduce confounding variables. In such cases, alternative carriers like&nbsp;<strong>KLH, BSA, or CRM197<\/strong>&nbsp;should be considered<a href=\"https:\/\/www.lifetein.com\/Peptide_Modifications_Carrier_Proteins.html?srsltid=AfmBOoqY3q8sJGx3gHeZ2g1ZoSyMNb2I1IqQBo4OBMSDMeLMPOpU8qSM\" target=\"_blank\" rel=\"noopener\"><\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"640\" height=\"480\" src=\"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/09\/OVA.webp\" alt=\"OVA\" class=\"wp-image-2981\" srcset=\"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/09\/OVA.webp 640w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/09\/OVA-300x225.webp 300w, https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2026\/09\/OVA-400x300.webp 400w\" sizes=\"(max-width: 640px) 100vw, 640px\" \/><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"conjugation-chemistry-and-practical-considerations\" class=\"wp-block-heading\">Conjugation Chemistry and Practical Considerations<\/h2>\n\n\n\n<h4 id=\"available-functional-groups\" class=\"wp-block-heading\">Available Functional Groups<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">OVA contains&nbsp;<strong>20 lysine residues<\/strong>, providing&nbsp;<strong>21 primary amines<\/strong>&nbsp;(including the N-terminus) available for conjugation. The most common conjugation strategies include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NHS-ester chemistry<\/strong>: Targets primary amines (lysine residues) for peptide coupling.<\/li>\n\n\n\n<li><strong>Maleimide-thiol chemistry<\/strong>: Enables site-specific conjugation to cysteine-containing peptides.<\/li>\n\n\n\n<li><strong>SMCC crosslinking<\/strong>: A heterobifunctional linker that couples amine-containing peptides to thiol-activated OVA.<\/li>\n<\/ul>\n\n\n\n<h4 id=\"conjugation-ratios-and-immunogenicity\" class=\"wp-block-heading\">Conjugation Ratios and Immunogenicity<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Research has shown that the&nbsp;<strong>conjugation ratio<\/strong>&nbsp;and&nbsp;<strong>molecular orientation<\/strong>&nbsp;of the peptide on the carrier can influence antibody affinity and titer. Optimizing these parameters is essential for generating high-quality antibodies.<\/p>\n\n\n\n<h4 id=\"commercial-availability\" class=\"wp-block-heading\">Commercial Availability<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Specialized providers such as&nbsp;<strong>LifeTein<\/strong>&nbsp;offer custom OVA conjugation services as part of their peptide modification portfolio. Their services include conjugation to KLH, BSA, OVA, CRM197, and Blue Carrier Protein, with rigorous quality control to ensure high-purity conjugates<a href=\"https:\/\/www.lifetein.com\/Peptide_Modifications_Carrier_Proteins.html?srsltid=AfmBOoqY3q8sJGx3gHeZ2g1ZoSyMNb2I1IqQBo4OBMSDMeLMPOpU8qSM\" target=\"_blank\" rel=\"noopener\"><\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/www.lifetein.com\/peptide_synthesis_services.html?_gl=1*15bjc7l*_gcl_aw*R0NMLjE3NTIyNTk1NTEuQ2p3S0NBanc3TUxEQmhBdUVpd0FJZVhHSVpVMXFSOXh4MzJEX3d6U2NYYUx2aWhzLWYzMU1FZ3VOSDRhcW41NUJtZmM1RnN3MkdVR0tSb0NCS01RQXZEX0J3RQ..*_gcl_au*NzY2NTIxODguMTc1MTUyMjM4MQ..&amp;_ga=2.129734156.1835841867.1753856001-90406248.1735925224\" target=\"_blank\" rel=\"noopener\">Find out more about peptide synthesis here.<\/a><\/strong><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"frequently-asked-questions-faq\" class=\"wp-block-heading\">Frequently Asked Questions (FAQ)<\/h2>\n\n\n\n<h4 id=\"what-is-the-primary-use-of-ovapeptide-conjugates\" class=\"wp-block-heading\">What is the primary use of OVA-peptide conjugates?<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The&nbsp;<strong>primary use<\/strong>&nbsp;of OVA-peptide conjugates is as a&nbsp;<strong>secondary carrier for screening and confirmation assays<\/strong>, particularly ELISA. They are used to confirm that antibodies generated against a peptide are specific to the peptide epitope rather than the carrier protein.<\/p>\n\n\n\n<h4 id=\"can-i-use-ova-for-primary-immunization-instead-of-klh\" class=\"wp-block-heading\">Can I use OVA for primary immunization instead of KLH?<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">While technically possible,&nbsp;<strong>OVA is not recommended for primary immunizations<\/strong>&nbsp;due to its lower immunogenicity compared to KLH. KLH remains the gold standard for generating high-titer antibodies against peptide antigens.<\/p>\n\n\n\n<h4 id=\"why-do-i-need-a-different-carrier-for-immunization-and-screening\" class=\"wp-block-heading\">Why do I need a different carrier for immunization and screening?<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The immune system generates antibodies against&nbsp;<strong>both the peptide and the carrier protein<\/strong><a href=\"https:\/\/www.lifetein.com\/Peptide_Modifications_Carrier_Proteins.html?srsltid=AfmBOoqY3q8sJGx3gHeZ2g1ZoSyMNb2I1IqQBo4OBMSDMeLMPOpU8qSM\" target=\"_blank\" rel=\"noopener\"><\/a>. If you use the same carrier for immunization and screening (e.g., BSA for both), you will detect antibodies against the carrier, leading to&nbsp;<strong>false-positive signals<\/strong><a href=\"https:\/\/www.lifetein.com\/Peptide_Modifications_Carrier_Proteins.html?srsltid=AfmBOoqY3q8sJGx3gHeZ2g1ZoSyMNb2I1IqQBo4OBMSDMeLMPOpU8qSM\" target=\"_blank\" rel=\"noopener\"><\/a>. Using a different carrier for screening (e.g., OVA) ensures that you are detecting only peptide-specific antibodies.<\/p>\n\n\n\n<h4 id=\"how-does-ova-compare-to-bsa-as-a-carrier\" class=\"wp-block-heading\">How does OVA compare to BSA as a carrier?<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>OVA<\/strong>\u00a0(45 kDa) is slightly smaller than\u00a0<strong>BSA<\/strong>\u00a0(67 kDa). Both are used as secondary carriers for screening. However, because BSA is ubiquitously used as a blocking agent in immunoassays,\u00a0<strong>OVA is often preferred for screening<\/strong>\u00a0to avoid cross-reactivity with anti-BSA antibodies that may be present in the antiserum.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Peptide-carrier protein conjugation\u00a0is a cornerstone technique in immunology, enabling the production of high-affinity antibodies against small peptide antigens. Because peptides alone (typically &lt;5,000 Da) are too small to elicit a robust immune response, they must be chemically linked to larger\u00a0carrier &hellip; <a href=\"https:\/\/www.lifetein.com\/blog\/ova-should-my-peptide-be-conjugated-to-it\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":2978,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-2945","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptide_synthesis"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Ovalbumin (OVA) occupies a distinct niche and requires a clear understanding of its properties, its optimal role in antibody workflows, and its limitations.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Jesse Zuccaro\"\/>\n\t<meta name=\"google-site-verification\" content=\"xKDW6DUiGuZ6nwglNeWlVWTgzTtMPzas13ROL63ytTc\" \/>\n\t<meta name=\"msvalidate.01\" content=\"5B15601215D876311F84CFEFB0F72F18\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.lifetein.com\/blog\/ova-should-my-peptide-be-conjugated-to-it\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"LifeTein Peptide Synthesis Blog\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"OVA: Should My Peptide Be Conjugated To It? | LifeTein Peptide Blog\" \/>\n\t\t<meta property=\"og:description\" content=\"Ovalbumin (OVA) occupies a distinct niche and requires a clear understanding of its properties, its optimal role in antibody workflows, and its limitations.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.lifetein.com\/blog\/ova-should-my-peptide-be-conjugated-to-it\/\" \/>\n\t\t<meta property=\"fb:admins\" content=\"233983946638783\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg\" \/>\n\t\t<meta property=\"article:tag\" content=\"peptide\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-09-03T16:59:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-09-03T16:59:02+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LifeTein-LLC-233983946638783\/\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@lifetein\" \/>\n\t\t<meta name=\"twitter:title\" content=\"OVA: Should My Peptide Be Conjugated To It? | LifeTein Peptide Blog\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Ovalbumin (OVA) occupies a distinct niche and requires a clear understanding of its properties, its optimal role in antibody workflows, and its limitations.\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@lifetein\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg\" \/>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"OVA: Should My Peptide Be Conjugated To It? | LifeTein Peptide Blog","description":"Ovalbumin (OVA) occupies a distinct niche and requires a clear understanding of its properties, its optimal role in antibody workflows, and its limitations.","canonical_url":"https:\/\/www.lifetein.com\/blog\/ova-should-my-peptide-be-conjugated-to-it\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"xKDW6DUiGuZ6nwglNeWlVWTgzTtMPzas13ROL63ytTc","msvalidate.01":"5B15601215D876311F84CFEFB0F72F18","miscellaneous":""},"schema":null,"og:locale":"en_US","og:site_name":"LifeTein Peptide Synthesis Blog","og:type":"article","og:title":"OVA: Should My Peptide Be Conjugated To It? | LifeTein Peptide Blog","og:description":"Ovalbumin (OVA) occupies a distinct niche and requires a clear understanding of its properties, its optimal role in antibody workflows, and its limitations.","og:url":"https:\/\/www.lifetein.com\/blog\/ova-should-my-peptide-be-conjugated-to-it\/","fb:admins":"233983946638783","og:image":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg","og:image:secure_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg","article:tag":["peptide"],"article:published_time":"2026-09-03T16:59:00+00:00","article:modified_time":"2026-09-03T16:59:02+00:00","article:publisher":"https:\/\/www.facebook.com\/LifeTein-LLC-233983946638783\/","twitter:card":"summary_large_image","twitter:site":"@lifetein","twitter:title":"OVA: Should My Peptide Be Conjugated To It? | LifeTein Peptide Blog","twitter:description":"Ovalbumin (OVA) occupies a distinct niche and requires a clear understanding of its properties, its optimal role in antibody workflows, and its limitations.","twitter:creator":"@lifetein","twitter:image":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg"},"aioseo_meta_data":{"post_id":"2945","title":null,"description":"Ovalbumin (OVA) occupies a distinct niche and requires a clear understanding of its properties, its optimal role in antibody workflows, and its limitations.","keywords":null,"keyphrases":{"focus":{"keyphrase":"OVA","score":0,"analysis":[]},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"Article","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","location":null,"local_seo":null,"seo_analyzer_scan_date":null,"breadcrumb_settings":null,"limit_modified_date":false,"open_ai":null,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2026-08-18 18:10:03","updated":"2026-09-03 17:01:16","focus_keyword":"OVA","additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.lifetein.com\/blog\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.lifetein.com\/blog\/category\/peptide_synthesis\/\" title=\"Peptide\">Peptide<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tOVA: Should My Peptide Be Conjugated To It?\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.lifetein.com\/blog"},{"label":"Peptide","link":"https:\/\/www.lifetein.com\/blog\/category\/peptide_synthesis\/"},{"label":"OVA: Should My Peptide Be Conjugated To It?","link":"https:\/\/www.lifetein.com\/blog\/ova-should-my-peptide-be-conjugated-to-it\/"}],"_links":{"self":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/posts\/2945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/comments?post=2945"}],"version-history":[{"count":2,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/posts\/2945\/revisions"}],"predecessor-version":[{"id":2983,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/posts\/2945\/revisions\/2983"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/media\/2978"}],"wp:attachment":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/media?parent=2945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/categories?post=2945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/tags?post=2945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}